Literature DB >> 17038430

Protection conferred by myocardial ATP-sensitive K+ channels in pressure overload-induced congestive heart failure revealed in KCNJ11 Kir6.2-null mutant.

Satsuki Yamada1, Garvan C Kane, Atta Behfar, Xiao-Ke Liu, Roy B Dyer, Randolph S Faustino, Takashi Miki, Susumu Seino, Andre Terzic.   

Abstract

Ventricular load can precipitate development of the heart failure syndrome, yet the molecular components that control the cardiac adaptive response to imposed demand remain partly understood. Compromised ATP-sensitive K(+) (K(ATP)) channel function renders the heart vulnerable to stress, implicating this metabolic sensor in the homeostatic response that would normally prevent progression of cardiac disease. Here, pressure overload was imposed on the left ventricle by transverse aortic constriction in the wild-type and in mice lacking sarcolemmal K(ATP) channels through Kir6.2 pore knockout (Kir6.2-KO). Despite equivalent haemodynamic loads, within 30 min of aortic constriction, Kir6.2-KO showed an aberrant prolongation of action potentials with intracellular calcium overload and ATP depletion, whereas wild-type maintained ionic and energetic handling. On catheterization, constricted Kir6.2-KO displayed compromised myocardial performance with elevated left ventricular end-diastolic pressure, not seen in the wild-type. Glyburide, a K(ATP) channel inhibitor, reproduced the knockout phenotype in the wild-type, whereas the calcium channel antagonist, verapamil, prevented abnormal outcome in Kir6.2-KO. Within 48 h following aortic constriction, fulminant biventricular congestive heart failure, characterized by exercise intolerance, cardiac contractile dysfunction, hepatopulmonary congestion and ascites, halved the Kir6.2-KO cohort, while no signs of organ failure or mortality were seen in wild-type. Surviving Kir6.2-KO developed premature and exaggerated fibrotic myocardial hypertrophy associated with nuclear up-regulation of calcium-dependent pro-remodelling MEF2 and NF-AT pathways, precipitating chamber dilatation within 3 weeks. Thus, K(ATP) channels appear mandatory in acute and chronic cardiac adaptation to imposed haemodynamic load, protecting against congestive heart failure and death.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17038430      PMCID: PMC1890387          DOI: 10.1113/jphysiol.2006.119511

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  68 in total

Review 1.  Current status of the E23K Kir6.2 polymorphism: implications for type-2 diabetes.

Authors:  Michael J Riedel; Diana C Steckley; Peter E Light
Journal:  Hum Genet       Date:  2004-11-23       Impact factor: 4.132

2.  ATP-sensitive K+ channel knockout compromises the metabolic benefit of exercise training, resulting in cardiac deficits.

Authors:  Garvan C Kane; Atta Behfar; Satsuki Yamada; Carmen Perez-Terzic; Fearghas O'Cochlain; Santiago Reyes; Petras P Dzeja; Takashi Miki; Susumu Seino; Andre Terzic
Journal:  Diabetes       Date:  2004-12       Impact factor: 9.461

Review 3.  ATP-sensitive K+ channel channel/enzyme multimer: metabolic gating in the heart.

Authors:  Alexey E Alekseev; Denice M Hodgson; Amy B Karger; Sungjo Park; Leonid V Zingman; Andre Terzic
Journal:  J Mol Cell Cardiol       Date:  2005-04-14       Impact factor: 5.000

Review 4.  The sulfonylurea controversy: more questions from the heart.

Authors:  P A Brady; A Terzic
Journal:  J Am Coll Cardiol       Date:  1998-04       Impact factor: 24.094

5.  Effects of sulfonylureas on left ventricular mass in type 2 diabetic patients.

Authors:  Tsung-Ming Lee; Mei-Shu Lin; Chang-Her Tsai; Chen-Ling Huang; Nen-Chung Chang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-08-25       Impact factor: 4.733

6.  Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.

Authors:  Ewan R Pearson; Isabelle Flechtner; Pål R Njølstad; Maciej T Malecki; Sarah E Flanagan; Brian Larkin; Frances M Ashcroft; Iwar Klimes; Ethel Codner; Violeta Iotova; Annabelle S Slingerland; Julian Shield; Jean-Jacques Robert; Jens J Holst; Penny M Clark; Sian Ellard; Oddmund Søvik; Michel Polak; Andrew T Hattersley
Journal:  N Engl J Med       Date:  2006-08-03       Impact factor: 91.245

7.  Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features.

Authors:  Peter Proks; Jennifer F Antcliff; Jon Lippiat; Anna L Gloyn; Andrew T Hattersley; Frances M Ashcroft
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-06       Impact factor: 11.205

Review 8.  Intracellular calcium release and cardiac disease.

Authors:  Xander H T Wehrens; Stephan E Lehnart; Andrew R Marks
Journal:  Annu Rev Physiol       Date:  2005       Impact factor: 19.318

9.  Gene knockout of the KCNJ8-encoded Kir6.1 K(ATP) channel imparts fatal susceptibility to endotoxemia.

Authors:  Garvan C Kane; Chen-Fuh Lam; Fearghas O'Cochlain; Denice M Hodgson; Santiago Reyes; Xiao-Ke Liu; Takashi Miki; Susumu Seino; Zvonimir S Katusic; Andre Terzic
Journal:  FASEB J       Date:  2006-11       Impact factor: 5.191

10.  Activating mutations in the ABCC8 gene in neonatal diabetes mellitus.

Authors:  Andrey P Babenko; Michel Polak; Hélène Cavé; Kanetee Busiah; Paul Czernichow; Raphael Scharfmann; Joseph Bryan; Lydia Aguilar-Bryan; Martine Vaxillaire; Philippe Froguel
Journal:  N Engl J Med       Date:  2006-08-03       Impact factor: 91.245

View more
  63 in total

1.  K(ATP) channels process nucleotide signals in muscle thermogenic response.

Authors:  Santiago Reyes; Sungjo Park; Andre Terzic; Alexey E Alekseev
Journal:  Crit Rev Biochem Mol Biol       Date:  2010-10-07       Impact factor: 8.250

2.  Reduction in number of sarcolemmal KATP channels slows cardiac action potential duration shortening under hypoxia.

Authors:  Zhiyong Zhu; Colin M-L Burnett; Gennadiy Maksymov; Elizabeth Stepniak; Ana Sierra; Ekaterina Subbotina; Mark E Anderson; William A Coetzee; Denice M Hodgson-Zingman; Leonid V Zingman
Journal:  Biochem Biophys Res Commun       Date:  2011-11-03       Impact factor: 3.575

Review 3.  Muscle KATP channels: recent insights to energy sensing and myoprotection.

Authors:  Thomas P Flagg; Decha Enkvetchakul; Joseph C Koster; Colin G Nichols
Journal:  Physiol Rev       Date:  2010-07       Impact factor: 37.312

4.  ATP-sensitive K(+) channel-deficient dilated cardiomyopathy proteome remodeled by embryonic stem cell therapy.

Authors:  Jelena Zlatkovic-Lindor; D Kent Arrell; Satsuki Yamada; Timothy J Nelson; Andre Terzic
Journal:  Stem Cells       Date:  2010-08       Impact factor: 6.277

Review 5.  KATP Channels in the Cardiovascular System.

Authors:  Monique N Foster; William A Coetzee
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

6.  Keeping the heart going: a new role for KATP channels.

Authors:  Paolo Tammaro; Frances M Ashcroft
Journal:  J Physiol       Date:  2006-10-26       Impact factor: 5.182

7.  Mice lacking sulfonylurea receptor 2 (SUR2) ATP-sensitive potassium channels are resistant to acute cardiovascular stress.

Authors:  Douglas Stoller; Rahul Kakkar; Matthew Smelley; Karel Chalupsky; Judy U Earley; Nian-Qing Shi; Jonathan C Makielski; Elizabeth M McNally
Journal:  J Mol Cell Cardiol       Date:  2007-08-01       Impact factor: 5.000

8.  Three C-terminal residues from the sulphonylurea receptor contribute to the functional coupling between the K(ATP) channel subunits SUR2A and Kir6.2.

Authors:  Julien P Dupuis; Jean Revilloud; Christophe J Moreau; Michel Vivaudou
Journal:  J Physiol       Date:  2008-05-01       Impact factor: 5.182

9.  Embryonic stem cell therapy of heart failure in genetic cardiomyopathy.

Authors:  Satsuki Yamada; Timothy J Nelson; Ruben J Crespo-Diaz; Carmen Perez-Terzic; Xiao-Ke Liu; Takashi Miki; Susumu Seino; Atta Behfar; Andre Terzic
Journal:  Stem Cells       Date:  2008-07-31       Impact factor: 6.277

Review 10.  KATP channels and cardiovascular disease: suddenly a syndrome.

Authors:  Colin G Nichols; Gautam K Singh; Dorothy K Grange
Journal:  Circ Res       Date:  2013-03-29       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.